Q-omics provides the consensus-scored SMIM14 profile across patient tissues and cancer cell-line models. SMIM14 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SMIM14 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, SMIM14 RNA expression shows 19,415 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, COAD, and UVM as cancer lineages where SMIM14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM14 survival associations across molecular data types. SMIM14 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM14 RNA expression–survival associations across cancer types. High SMIM14 expression shows favorable associations in HNSC, SKCM, UCEC, KIRC, MESO and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SMIM14 RNA expression.
This table summarizes SMIM14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SMIM14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM14 shows lower tumor expression in COAD, KICH, LUSC, READ, KIRC and BLCA. The COAD box plot shows higher SMIM14 RNA expression in normal versus tumor tissue (log2 FC = −2.072, t-test p < 0.001).
This table shows molecular features associated with SMIM14 in patient tissues and cancer cell lines. In patient samples, SMIM14 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
